Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model.

Jéssica Barreto Ribeiro Dos SantosMichael Ruberson Ribeiro da SilvaAlessandra Maciel AlmeidaFrancisco de Assis Acurcio Juliana Álvares Teodoro

Published in: Expert review of pharmacoeconomics & outcomes research (2020)

the utility among adalimumab, etanercept, and golimumab was similar and the cost was the component that most impacted the economic model. Therefore, depending on the agreed price with the drug manufacturers, the incremental cost-utility ratio may vary among them.

Keyphrases

rheumatoid arthritis
ankylosing spondylitis
disease activity
ulcerative colitis
rheumatoid arthritis patients
emergency department
systemic lupus erythematosus
idiopathic pulmonary fibrosis
systemic sclerosis
electronic health record